Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECST: Colestimide + elobixibat vs colestimide + placebo in NASH with dyslipidemia
jRCTs031200144Completed
- Sponsor
- Yokohama City University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and dyslipidemia comparing Colestimide + placebo with Colestimide + elobixibat (2 arms). Primary endpoint: Primary: Absolute change from baseline in ALT at Week 48. Started Jun 2021; status: completed.
02
Drugs
elobixibat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)dyslipidemia
Beyond the preview
Go deeper on jRCTs031200144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200144.